Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextroamphetamine + paroxetine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of dextroamphetamine, a central nervous system stimulant, and paroxetine, a selective serotonin reuptake inhibitor (SSRI). Dextroamphetamine works by increasing the release and preventing the reuptake of dopamine in synaptic clefts, while paroxetine works by inhibiting the reuptake of serotonin. This combination has been studied for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, particularly those with comorbid mood or anxiety disorders.
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on dextroamphetamine + paroxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextroamphetamine + paroxetine.